CYCLACEL PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.11 USD | +1.93% |
|
-0.47% | -20.97% |
| May. 02 | Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding | CI |
| Apr. 30 | Top Midday Gainers | MT |
Presenter SpeechChristopher Henney (Executives)Good morning. Welcome to the 2020 Annual Meetin...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.11
USD
Average target price
11
USD
Spread / Average Target
+421.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.97% | 2.78M | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +6.72% | 23.47B | |
| -13.89% | 21.9B | |
| -6.64% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- CYCC Stock
- News Cyclacel Pharmaceuticals, Inc.
- Transcript : Cyclacel Pharmaceuticals, Inc. - Shareholder/Analyst Call